NCT06248606View on ClinicalTrials.gov

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

August 31, 2028

Conditions
Non Small Cell Lung CancerNSCLCKRAS G12C
Interventions
DRUG

Adagrasib

Adagrasib 600mg orally

RADIATION

Stereotactic Radiosurgery

Delivered as per standard of care

Trial Locations (1)

22908

RECRUITING

University of Virginia Health System, Charlottesville

Sponsors

Collaborators (1)

Mirati Therapeutics Inc.
All Listed Sponsors
collaborator

Mirati Therapeutics Inc.

INDUSTRY

collaborator

University of Virginia

OTHER

lead

Ryan Gentzler, MD

OTHER

NCT06248606 - Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | Biotech Hunter | Biotech Hunter